Skip to main content
Clinic Retatrutide

An editorial reading desk for the triple-agonist clinical record — Phase 2, TRIUMPH Phase 3, and what the trials actually measured.

Retatrutide Questions Answered in Plain Words

These short answers come from published Retatrutide studies. Each number has a citation mark. The clinical trial data page lists the full sources. The frequently asked questions below cover what the drug did, what went wrong, and what isn't known.

What does Retatrutide copy in the body?

Eli Lilly made Retatrutide. It is still being studied. The study drug was given as one weekly shot under the skin.

Retatrutide has three hormone actions. One lowers hunger and helps insulin. A second helps insulin after meals. The last may increase fuel use. Phase 2 papers appeared in two medical journals in 2023 [1][2]. Phase 3 TRIUMPH results began appearing in 2025 [5].

What does Retatrutide copy in the body?

How does Retatrutide work?

Retatrutide has three hormone actions. The first copies GLP-1, a hormone that lowers hunger and helps insulin. It also slows the stomach. The second action helps release insulin and manage stored fat.

The third may help burn liver fat. It may also act on brown fat, a body fat that burns fuel to make heat. That extra action separates retatrutide from two-action drugs [13]. The three actions still can't show how your body would respond.

What is the FDA approval status of Retatrutide?

Retatrutide has no FDA approval and remains investigational. An ordinary prescription cannot authorize its use outside a clinical trial. Large Phase 3 TRIUMPH studies were still running.

There is no routine prescription route for retatrutide. Supervised human use takes place in authorized research studies. A court sent the choice between two legal review paths back to the FDA in September 2025. The choice was still open [5]. Clinical trial results do not confer approval for prescription sale.

What do studies say about Retatrutide safety?

Phase 2 found mostly nausea, vomiting, diarrhea, and constipation. Those problems were usually mild or moderate. They eased after the study amount stopped rising [10]. The Phase 2 record was short.

The human studies found no major warning for the thyroid, pancreas, or heart. Related GLP-1 drugs, which copy one hunger hormone, still carry warnings. Phase 3 is checking long-term safety [20]. A short study can't settle your lifetime risk.

What risks did Retatrutide studies find?

In Phase 2, nausea affected up to 60% on 12 mg while the amount rose. Diarrhea affected 15–33%, vomiting 21–26%, and constipation 10–20%. Larger doses brought more trouble [10]. Resting hearts beat 2–4 more times each minute [20]. Reviews of related GLP-1 drugs, which copy one hunger hormone, suggest about 75.6% of lost weight may return after stopping [18]. Those group rates can't predict your own side effects.

What serious Retatrutide dangers remain under study?

Serious problems were uncommon in Phase 2. Pancreatitis didn't rise above placebo, the dummy shot. Related hunger drugs caused changes in certain thyroid cells in rodents. Human Phase 2 blood tests did not find those changes.

Large Phase 3 studies still watch the thyroid and gallbladder [20]. At 12 mg, gut problems caused the highest leaving rate. That 12 mg rate was 11.3% in TRIUMPH-1 [17]. The short study can't settle your long-term risk.

What happens when Retatrutide stops?

Related GLP-1 drugs, which copy one hunger hormone, often bring weight regain after they stop. One review combined studies of those drugs. Regain leveled near 75.6% of weight lost [18]. That figure may not fit retatrutide.

Phase 3 TRIUMPH follow-up hasn't given a retatrutide-only answer. Retatrutide has a 6-day half-life. That span tells when blood has lost half. Blood levels may take about 4–5 weeks to become very low [19].

What did Retatrutide change in the studies?

In Jastreboff's 2023 Phase 2 study, the 12 mg group lost a mean 24.2% by 48 weeks [1]. Sanyal's 2024 liver study found 82.4% less liver fat at 24 weeks [3]. Coskun's 2025 body scans found 31.4% less deep belly fat at 36 weeks [6]. In diabetes, the three-month blood sugar test fell 2.02% at 36 weeks [2]. A common blood fat fell 40.6%, cholesterol outside the protective kind fell 26.9%, and blood pressure fell up to 11.8 mmHg [11][16]. Those group means can't predict your own changes.

When could Retatrutide become available?

Eli Lilly announced early Phase 3 TRIUMPH-1 results in 2025 [5]. A filing or a study announcement does not establish a prescription launch date. Retatrutide is still investigational.

Retatrutide cannot be supplied as a routine prescription medicine. This page gives no predicted date for prescription access. Any future prescription route would require the relevant regulatory decisions first.

What does the Retatrutide half-life mean?

The half-life is about 6 days in people. A small Phase 1 study found that timing. Phase 2 groups backed it up [19]. Half-life means blood takes that long to lose half the drug.

Two drug changes slow removal. One blocks a blood enzyme that breaks down the matching natural hormone. The other keeps the drug with a blood protein. Those changes supported one weekly study shot in Phase 2 and Phase 3. A level blood amount took about 4–5 weeks. At week 4, the amount could still be building.

When did Retatrutide changes first show up?

Less hunger may begin in the first 1–2 weeks. Measured weight loss often appeared in weeks 4–8. In the Phase 2 weight study, the 12 mg group had lost 12.9% by 24 weeks.

Loss reached 24.2% at 48 weeks [1]. Weight kept falling through that 48-week span. Phase 3 TRIUMPH-1 checked 80 weeks and found 28.3% mean loss on 12 mg [5].

What does the Retatrutide GLP-3 nickname mean?

GLP-3 is an informal nickname for Retatrutide. Here, 3 counts the drug's three hormone actions. The nickname isn't a formal medical name.

GLP-1 is a hunger and blood sugar hormone. GLP-2 mainly acts in the gut. That GLP-2 hormone isn't part of retatrutide. Those names explain why the nickname can mislead.

Researchers call retatrutide a three-hormone drug. The GLP-3 nickname says little about study results or safety.

What separates Retatrutide from Tirzepatide?

Tirzepatide copies two hormone messages. Retatrutide adds a third action. That extra action may raise fuel use. A 2024 review of separate studies found 22.10% weight loss on 12 mg retatrutide.

The top two-action result was 16.53% [9]. The drugs haven't met in one direct study. Both mainly caused gut problems. Separate figures can't settle which drug works better.

What does lab mixing of Retatrutide involve?

Labs receive some test samples as freeze-dried powder. Researchers add germ-free water before testing. One report described a test liquid with 1 mg in 1 mL.

Those figures describe a lab sample. They don't give you a home recipe. Lilly gave study patients ready-mixed auto-injector pens. Outside powder has no FDA check for safety or germs.

What storage did Retatrutide lab plans describe?

Labs kept freeze-dried powder at -20°C for long storage. Repeated freezing and thawing can harm it. After lab mixing, the liquid stayed at 2–8°C in a refrigerator for 28–30 days.

The liquid wasn't frozen and stayed out of light. These facts come from lab plans, not an FDA label. Retatrutide has no approved prescribing label.

Who made Retatrutide and runs its studies?

Eli Lilly and Company made Retatrutide. Lilly sponsors all listed studies. ClinicalTrials.gov lists the Phase 2 weight study and the type 2 diabetes study.

The public list also has TRIUMPH-1, the Phase 3 weight study. Each study page names its locations and contacts. Those details help you ask whether a study is enrolling.

What health problems is Retatrutide being studied for?

The main work asks whether Retatrutide helps adults with obesity lose weight. Phase 3 also studies type 2 diabetes and MASLD fatty liver disease. Other work checks knee arthritis pain after weight loss.

TRIUMPH-4 reported that work in 2025 [8]. Studies also cover sleep apnea and heart risk in TRIUMPH-3. No clinical use has FDA approval.

Do Retatrutide side effects start right away?

In Phase 2, nausea and vomiting were worst while the amount rose. That was during weeks 1–8. Some people felt sick within hours of the first shot [10].

Problems often eased after the amount stayed level. The 12 mg group had the most gut trouble. It also had the most weight loss once the amount stayed level.

What changed over time in Retatrutide studies

Less hunger may begin in the first 1–2 weeks. Nausea, constipation, and vomiting were worst as the amount rose in weeks 1–8. Measured weight loss often appeared in weeks 4–8.

Study patients also spoke of more fullness and changed energy. Phase 2 checked the full result at 24 and 48 weeks [1]. Those Phase 2 time marks don't promise your pace. Phase 3 TRIUMPH-1 made its main check at 80 weeks [5].

What did Retatrutide do to belly and liver fat?

Phase 2 body scans found 31.4% less deep belly fat at 36 weeks. That was in the 8 mg diabetes group in Coskun's 2025 report [6]. Researchers think the third hormone action helps break down stored fat. A special liver scan found 82.4% less liver fat at 24 weeks in the Phase 2a liver study [3]. These are group results, not a promise for you.

What do Retatrutide and Tirzepatide results prove?

Separate Phase 2/3 studies hint at more weight loss with Retatrutide. A 2024 review found 22.10% on 12 mg retatrutide. The top dual-drug figure was 16.53% [9].

No head-to-head study existed by mid-2026. TRIUMPH-5 is planned for that direct test. Side effects look much alike. Retatrutide's glucagon action may burn more fuel, but the indirect figures can't prove it is better.

What limits Retatrutide availability in the United States

In the United States, retatrutide remains investigational rather than a medicine a clinician can prescribe. Authorized trial enrollment is the route for supervised human use. Early Phase 3 TRIUMPH-1 results came out in 2025 [5].

A reported trial result does not establish permission for prescription sale. The agency also had to choose between two legal review routes. Retatrutide has no routine prescription pathway. Research-labelled powder continues to be sold without FDA approval for safety or effect.

What is the Retatrutide dosage schedule in studies?

TRIUMPH Phase 3 began at 2.5 mg once a week in weeks 1–4. The study amount rose by 2.5 mg every 4 weeks. Its top set amount was 12 mg per week [5].

Phase 2 began at 2 mg and used much the same slow rise. The slower pace was meant to ease stomach and bowel trouble [10]. Study staff gave a weekly shot beneath the skin.

What weekly Retatrutide amounts did studies test?

Phase 2 tested 0.5, 1, 4, 8, and 12 mg through one weekly shot placed below the skin. The largest studied amount was 12 mg per week. Phase 3 TRIUMPH-1 tested 4 mg, 9 mg, and 12 mg.

No paper has reported more than 12 mg weekly. The drug's 6-day half-life supports the weekly timing [19]. These are study amounts, not a personal dose.

What could delay Retatrutide approval

Results from Phase 3 TRIUMPH-1 and TRIUMPH-4 were announced in 2025 [5][8]. Results and review filings do not set a date when a clinician may prescribe the drug. No prescription opening date is established here.

Retatrutide remains outside ordinary prescription care. A September 2025 court ruling sent the choice between two legal review routes back to the FDA. Routine prescribing remains dependent on the necessary regulatory decisions.

What is Retatrutide's status outside the USA?

Retatrutide remains investigational and has no routine prescription route. An investigational study is distinct from an authorization to market a prescription drug. Approval cannot be inferred from the presence of trial sites in a country.

A submission for review does not itself permit prescribing. Published results do not change retatrutide's investigational status. Authorized studies govern supervised human use; research-labelled material remains on sale without approval for use in people.